- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05238155
Evaluation of the Impact of Reduced Immunosuppression
Evaluation of the Impact of Reduced Immunosuppression on Graft-versus-host Disease and Rejection Rates in Orthotopic Liver Transplant Recipients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
GVHD is commonly observed in allogeneic hematopoietic stem cell transplantation recipients but can also occur in recipients of solid organ transplantation , with the first case of GVHD in a SOT recipient described in 1984. While the exact incidence of SOT-associated GVHD has not been determined due to challenges with identifying and diagnosing GVHD in SOT recipients, the reported incidence of GVHD following orthotopic liver transplantation ranges from 0.1%-2%, one of the highest rates among SOT recipients. Although it occurs very rarely with SOT, GVHD leads to poor patient outcomes, with a mortality rate exceeding 75%. Risk factors for SOT-associated GVHD have not been clearly defined, but possible risk factors have been identified, such as recipient age ≥65 years, donor-recipient age difference of ≥40 years, degree of human leukocyte antigen matching, level of immunosuppression, and history of hepatocellular carcinoma.
There are currently no guideline recommendations for treatment or prevention of GVHD in SOT patients. Current treatment strategies include a combination of increasing immunosuppression, decreasing immunosuppression, or changing immunosuppression agents, making it difficult to definitively determine an effective treatment approach.
However, it has been postulated that decreasing immunosuppression may allow the transplant recipient's native immune system to reject donor lymphocytes and would therefore act protectively against GVHD in these patients. Since there is currently no clinical outcomes data to support this and because GVHD is a very rare occurrence in this population, reducing immunosuppression as a preventative measure for GVHD is not a commonplace practice amongst SOT centers.
The Liver Institute at Methodist Dallas Medical Center (MDMC) is a comprehensive, multidisciplinary disease management center. One of its services is OLT with life-long outpatient follow-up. When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests consideration for the omission of the antimetabolite at discharge if there is a donor-recipient age discrepancy (DAD) that is greater than 30 years. This change was made with the intention to reduce the risk of GVHD, given that a greater disparity in donor-recipient age may put these patients at a higher risk for GVHD.
Since this protocol implementation, the exact clinical implications of this reduction in immunosuppression are still unclear. While this approach may reduce the incidence of GVHD, omission of the antimetabolite in maintenance immunosuppression regimens puts these OLT recipients at risk for rejection of their graft, which can also be a life-threatening complication. Evaluation of the clinical outcomes related to this protocol change is warranted in order to appropriately weigh the risks versus benefits of reducing immunosuppression to prevent GVHD.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Methodist Dallas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 18 years
- Received OLT or CKLT during study period
Exclusion Criteria:
- Recipients requiring re-transplant within one month post-transplant
- Recipients who died of a cause other than GVHD within one month post-transplant
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Orthotopic Liver Transplantation recipients prior to protocol implementation date
Orthotopic Liver Transplantation recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
|
When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
|
Orthotopic Liver Transplantation recipients after protocol implementation date
Over the last several years, there have been changes made to this protocol, and the current protocol now suggests consideration for the omission of the antimetabolite at discharge if there is a donor-recipient age discrepancy that is greater than 30 years.
This change was made with the intention to reduce the risk of GVHD, given that a greater disparity in donor-recipient age may put these patients at a higher risk for GVHD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of GVHD at one year post-transplant
Time Frame: September 12, 2004 to June 30, 2020
|
Diagnosis confirmed with donor lymphoid chimerism
|
September 12, 2004 to June 30, 2020
|
Graft rejection at one year post-transplant
Time Frame: September 12, 2004 to June 30, 2020
|
Diagnosis confirmed by liver biopsy
|
September 12, 2004 to June 30, 2020
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jessica Crotty, PharmD, Methodist Health System
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 041.PHA.2021.D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft Vs Host Disease
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Rambam Health Care CampusWithdrawnFecal Microbiota Transplantation in Graft vs. Host DiseaseIsrael
-
Novartis PharmaceuticalsCompletedCorticosteroid Refractory Acute Graft vs Host DiseaseGermany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
-
Washington University School of MedicineCompletedGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Boston Children's HospitalBristol-Myers SquibbRecruitingGraft Vs Host DiseaseUnited States
-
Christopher DvorakRecruitingGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Fred Hutchinson Cancer CenterFacet BiotechUnknownGraft-vs-Host DiseaseUnited States
-
Rabin Medical CenterUnknownGraft Vs Host DiseaseIsrael
Clinical Trials on antimetabolite
-
University of California, DavisCareDxRecruitingCOVID-19 | Immunosuppression | Vaccine Response ImpairedUnited States
-
University of PittsburghTerminatedAcute Myeloid LeukemiaUnited States
-
PrECOG, LLC.Celgene CorporationCompletedCholangiocarcinomaUnited States, Austria
-
University of Health Sciences LahoreRecruitingProliferative VitreoretinopathyPakistan
-
Columbia UniversityPfizer; Cornell UniversityCompleted
-
University of PisaAzienda Ospedaliero, Universitaria PisanaUnknownGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Colo-rectal Cancer | Liver Cancer | Biliary Tract Cancer | Gall Bladder CancerItaly
-
Lund University HospitalDanish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaboratorsRecruitingBreast Cancer | Triple Negative Breast NeoplasmsDenmark, Sweden
-
St. Jude Children's Research HospitalNational University, SingaporeCompletedLymphoblastic LymphomaUnited States